Theravance reports Q4/FY2025 financials; restructuring after Phase 3 failure; strategic review ongoing

Theravance Biopharma, Inc.

Q4/FY2025: YUPELRI net sales $266.6M (+12% YoY); triggered $25M milestone.
TRELEGY net sales $3.9B (+12% YoY) triggered $50M milestone; confident in $100M 2026 milestone.
Restructuring after failed Phase 3 CYPRESS study; expects $60-70M annualized cash savings starting Q3 2026.
Cash ~$400M at end Q1 2026; no debt.
Strategic Review Committee accelerating evaluation of alternatives including potential sale of company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.